Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxocobalamin Chloride in Pediatric cblC-type Methylmalonic Acidemia
NCT07163364Phase 3Not yet recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Aug 2025
- Primary completion
- Oct 2026
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
A Phase 3 trial of hydroxocobalamin in methylmalonic acidemia (MMA), sponsored by CSPC ZhongQi Pharmaceutical Technology. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
hydroxocobalamin
03
Conditions
methylmalonic acidemia (MMA)
Beyond the preview
Go deeper on NCT07163364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07163364.